This episode explores how earlier relapse in multiple myeloma is creating a tougher treatment landscape, especially for patients already resistant to lenalidomide and anti-CD38 therapy. The hosts break down MajesTEC-9, where teclistamab delivered major efficacy gains but also brought significant infection risk, CRS, and new logistical challenges for early-relapse care.

A deep dive into the REDUCE-AMI trial and what it means for patients recovering from a heart attack with preserved ejection fraction. The hosts examine why beta-blockers may no longer provide the same benefit in the modern PCI era, and where deprescribing fits in without abandoning patients who still need the drug.

Show Notes

• Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute ...: https://www.tctmd.com/news/another-beta-blocker-blow-reduce-ami-confirms-no-benefit-after-acute-mi

This episode breaks down how transthyretin misfolding drives ATTR cardiomyopathy, comparing tafamidis stabilization with vutrisiran’s RNAi gene-silencing approach. The hosts also unpack HELIOS-B results, functional outcomes, and the real-world challenge of whether costly combination therapy is worth it.

Show Notes

• Vutrisiran in Patients with Transthyretin Amyloidosis ...: https://www.nejm.org/doi/abs/10.1056/NEJMoa2409134
• Contextualizing the results of HELIOS-B in the broader ... - PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11805581/
• Alnylam Announces FDA Approval of AMVUTTRA ...: https://investors.alnylam.com/press-release?id=28831

We unpack the biological case against hyperoxia after cardiac arrest, then examine the large LOGICAL trial and its surprising finding: tightly restricting oxygen did not improve six-month neurological recovery compared with a more liberal approach.

A deep dive into why blood clots are a risk after hip and knee replacement, and how modern care has driven rates so low. The hosts unpack the EPCAT III trial, showing aspirin can be noninferior to rivaroxaban for many routine patients while also reducing cost and discharge headaches.

This episode explores how obesity treatment is moving from single-pathway GLP-1 drugs to dual and triple agonists like tirzepatide and retatrutide, with a look at the biology behind better weight-loss results. It also examines what the new data may mean for sleep apnea, cardiovascular risk, kidney disease, liver health, and the practical limits of long-term use, side effects, and access.